Home > News > BioSante and U.S. Army Co-Developing Ricin Vaccine for Biodefense
February 3rd, 2004
BioSante and U.S. Army Co-Developing Ricin Vaccine for Biodefense
BioSante Pharmaceuticals, Inc. reiterated today its Cooperative Research and Development Agreement with the U.S. Army's Medical Research Institute of Infectious Diseases for the development of a needle-free vaccine against ricin, a poisonous substance thought to have been detected in a U.S. Senate mailroom this week. BioSante has provided BioVant(TM), its proprietary nanoparticulate-based vaccine adjuvant and delivery system, and the Army has provided recombinant antigens to be used in potential vaccines against various bioterrorism agents.
Teijin to Participate in Nano Tech 2015 January 22nd, 2015
2nd International Conference on Infectious Diseases & Nanomedicine (December 15-18, 2015, Kathmandu, NEPAL) January 22nd, 2015
Anti-microbial coatings with a long-term effect for surfaces – presentation at nano tech 2015 in Japan January 21st, 2015
A spoonful of sugar in silver nanoparticles to regulate their toxicity January 21st, 2015